Some notice mild nausea during the first 2 to 3 days after the initial injection
While it is still not FDA-approved, it is being clinically tested and studied as a solution for obesity
Y.et al
Final Verdict Willows fundamentals are genuinely strong: 97/100 in Legitimacy & Credentials, perfect Patient Support ( 100/100 ), flat-rate pricing with no hidden fees, and solid medication packaging (88/100 )
The drug was approved by the US FDA in June 2021 as a 2.4 mg once-weekly injection for chronic weight management in adults with obesity or those overweight with at least one weight-related condition, such as high blood pressure, Type 2 diabetes or high cholesterol.3 In 2023, according to market information from Midas (IQVIA), sales of semaglutide for weight management more than quadrupled year-on-year, and further interest has been spurred by new indications related to reducing cardiovascular risk, and emerging benefits are being shown in people with Alzheimers disease.4,5 The strength of these figures clearly demonstrates the intense demand for GLP-1 treatments, but it does not convey the unforeseen implications of such high levels of popularity
/assets/images/provider/photos/2826746.png)
